Of the six proteins/complexes in this route, EGFR, ERBB2, and the 3-phosphoinositide-dependent protein kinase 1 (PDPK1)43, 44 were known primary target of marketing anti-cancer drugs. This evidence concerns the gene EGFR and cancer.